Shots:
- Nosis Biosciences has entered into a strategic collaboration with Janssen Biotech (subsidiary of J&J) to design & develop cell-targeted RNA medicines
- The collaboration leverages J&J’s drug discovery & clinical expertise as well as Nosis’ Connexa platform to design drugs with extra-hepatic access to multiple & hard-to-target cell types involved in chronic diseases
- Connexa is an AI-powered platform that integrates proprietary atlas of cell-specific internalizing receptors, physics-aware machine learning, generative AI drug design, & high-throughput in vivo data to accelerate development of cell-targeted therapies
Ref: Nosis Biosciences | Image: Nosis Biosciences and Johnson & Johnson
Related News:- The US FDA Approves sNDA for J&J’s Spravato (esketamine) to Treat Major Depressive Disorder (MDD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
